Evidence map›Paper›PMID 30181504›Full record

ArticleVaccines2018

Novel Whole-Cell Inactivated

Rikhav P Gala, Rokon Uz Zaman, Martin J D'Souza, Susu M Zughaier

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Clinical microbiology reviews · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rikhav P GalaVaccine Nanotechnology Laboratory, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA. rikhav.praful.gala@gmail.com.
Rokon Uz ZamanVaccine Nanotechnology Laboratory, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA. rokonuz.zaman@live.mercer.edu.
Martin J D'SouzaVaccine Nanotechnology Laboratory, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA. DSOUZA_MJ@mercer.edu.
Susu M ZughaierDepartment of Basic Medical Sciences, College of Medicine, Qatar University, Doha 2713, Qatar. szughaier@qu.edu.qa.ORCID 0000-0001-7487-8770
Mercer University · USQatar University · QA

Funding

Whole cell Neisseria gonorrhoeae micro particulate vaccineR15AI133473 · NIAID · MERCER UNIVERSITY MACON · PI D'SOUZA, MARTIN J. · 2018 to 2018
$463k
Henry M. Jackson Foundation Sub-Award from 1U19AI113170-01NIAID NIH HHS R15 AI133473
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antigen-specific antibodyantigen-specific CD4 T lymphocytesgonorrheamicroneedlenanotechnologyNeisseria gonorrhoeaeskin patchvaccine

Identifiers

PMID30181504
PMCPMC6161099
OpenAlexW2884350335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.